Latest Articles

Dr. Jennifer Mann, associate director of Science at UK Biocentre, explains why a blind spot in current direct-to-consumer genetic testing practices requires closer analysis and change.

We spoke with Dr. Niranjan Bose, managing director, Health & Life Sciences Strategy, Gates Ventures, about how proteomics-based biomarkers and international partnerships are changing the future of neurodegenerative disease research.

This article explores how mass spectrometry and emerging analytical techniques are helping researchers decode the aging proteome at multiple scales – from plasma to specific tissues to individual organelles.

Researchers are investigating blood-based biomarkers like pTau217 for Alzheimer’s detection, offering a less invasive alternative to traditional methods. However, challenges remain due to the interference of proteins from other organs.

Learn how specific miRNA signatures have potential as metastatic colorectal cancer biomarkers, enhancing non-invasive detection and patient risk stratification.

Learn about the potential of EEG biomarkers in the early detection and monitoring of neurological diseases such as Alzheimer's with Dr. Javier Escudero, reader in biomedical signal processing at the University of Edinburgh.

By improving sensitivity and boosting signal amplification, nanomaterials are heralding a new era for biomarker detection.

GLP-1 drugs like semaglutide and tirzepatide show promise in treating obesity, with benefits including weight loss and improved metabolic health. However, concerns about long-term safety, cost, and accessibility remain.

Spatial transcriptomics is just the start – learn why spatial proteomics is essential to fully understand cell function and disease mechanisms in this thought piece from Dr. Nikhil Rao, CCO at Syncell.

Explore how digital biomarkers are transforming clinical trials with real-time data, continuous monitoring and AI-driven patient insights.